Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2013

View Archived Issues

Report on first-in-man evaluation of a new gene transfer vector for PAD

Novel NURR1-RXR agonist shows promise in animal model of Parkinson's disease

Opicapone useful as levodopa-sparing agent in patients with PD

Celon Pharma identifies novel GSK-3 beta inhibitors for AD

Alligator Bioscience and BioInvent International design new antibodies for cancer

ChronTech reports interim data from phase II ChronVac-C study

Ra Pharmaceuticals collaborates with Merck & Co. on Cyclomimetics

Transfer of rights to exenatide completed in Japan

BIND Therapeutics and Pfizer to develop multiple Accurins

Description of the first reported case of CYP51A1 deficiency in humans

Phase I study begins for ISIS-APOARx

MedImmune acquires AlphaCore Pharma

VivaGel reduces risk of recurrent bacterial vaginosis in phase II study

Positive topline results reported from phase II clinical trial of RSV vaccine

Merck & Co. presents new CMV vaccines

Idenix Pharmaceuticals prepares new agents for HCV infection

Merck Serono and BioMed X enter collaboration to conduct research projects in oncology

Genzyme and Sanofi give update on Evoltra in Japan

EAU strengthens recommendation for Hexvix in bladder cancer

Aspireo reports encouraging results from phase IIa study of somatoprim in acromegaly

AS-1069562 shows promise in animal models of neuropathic pain

Novel gamma-secretase inhibitors disclosed by Merck & Co.

Sage Therapeutics synthesizes novel NMDA receptor modulators

Roche launches new thyroid cancer test

GSK obtains approval for quadrivalent seasonal flu vaccine in Germany and the U.K.

Navidea and Molecular Neuroimaging enroll first subject in NAV-5001 study

GlaxoSmithKline begins phase III study of Benlysta in patients with vasculitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...